Edition:
United Kingdom

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

125.55GBp
18 Jan 2019
Change (% chg)

1.00 (+0.80%)
Prev Close
124.55
Open
124.40
Day's High
128.75
Day's Low
123.20
Volume
2,074,315
Avg. Vol
3,968,697
52-wk High
504.60
52-wk Low
75.48

Latest Key Developments (Source: Significant Developments)

Indivior Says Expects More Players In The Generic Suboxone Market - Conf Call
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Indivior PLC ::INDIVIOR SAYS EXPECTS MORE PLAYERS IN THE GENERIC SUBOXONE MARKET WITH POTENTIAL FOR THREE PLAYERS, CO’S AUTHORIZED GENERIC BEING FOURTH - CONF CALL.INDIVIOR SAYS THERE HAS BEEN INITIAL NET REVENUE FROM PERSERIS IN FY 2018, MATERIAL CONTRIBUTION EXPECTED TO BEGIN IN 2019 AND BEYOND - CONF CALL.  Full Article

Indivior Says Federal Court Declines Immediate Issue Of Mandate
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Indivior PLC ::FEDERAL COURT DECLINES IMMEDIATE ISSUE OF MANDATE.COURT OF APPEALS FOR FEDERAL CIRCUIT DECLINES TO IMMEDIATELY ISSUE MANDATE AFTER PRELIMINARY INJUNCTION RULING.U.S. COURT DENIED DR. REDDY'S MOTION TO IMMEDIATELY ISSUE MANDATE FOLLOWING CAFC'S RULING VACATING PRELIMINARY INJUNCTION.CAFC ALSO ORDERED THAT ANY PETITION FOR REHEARING BE SUBMITTED ON OR BEFORE DECEMBER 20, 2018.REDDY'S WILL REMAIN ENJOINED FROM RESUMING "AT-RISK" U.S. LAUNCH OF GENERIC BUPRENORPHINE-NALOXONE SUBLINGUAL FILM TILL AFTER MANDATE ISSUES.  Full Article

FMR LLC Cuts Stake In Indivior To Below 5 Pct From 9.99 Pct - Filing
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Indivior PLC ::FMR LLC CUTS STAKE IN INDIVIOR PLC TO BELOW 5 PERCENT FROM 9.99 PERCENT - FILING.  Full Article

Indivior Says Health Canada Approves Sublocade
Friday, 23 Nov 2018 

Nov 23 (Reuters) - Indivior PLC ::HEALTH CANADA APPROVES SUBLOCADE.HEALTH CANADA HAS APPROVED SUBLOCADE (BUPRENORPHINE EXTENDED-RELEASE) INJECTION FOR SUBCUTANEOUS USE.IN CANADA, SUBLOCADE WILL BE MARKETED BY INDIVIOR CANADA AND WILL BE AVAILABLE BY SECOND HALF OF 2019.  Full Article

Standard Life Aberdeen Aggregate Raises Stake To 13.61 Pct In Indivior
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Indivior PLC ::AGGREGATE OF STANDARD LIFE ABERDEEN RAISES STAKE TO 13.61 PERCENT FROM 12.1 PERCENT IN INDIVIOR PLC - FILING.  Full Article

Indivior Responds To Court Decision Related To Dr. Reddy's Laboratories
Wednesday, 21 Nov 2018 

Nov 21 (Reuters) - Indivior PLC ::INDIVIOR RESPONDS TO FEDERAL COURT DECISION.SAYS FY 2018 GUIDANCE REMAINS VALID UNTIL SUCH TIME A GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM ENTERS MARKET IN 2018.SAYS WILL CONTINUE TO DEFEND ITS INTELLECTUAL PROPERTY AND IMPLEMENT CONTINGENCY PLAN.  Full Article

Indivior Says Court Lifts Injunction Barring Dr. Reddy's From Selling Generic Version Of Suboxone
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - Indivior PLC ::INDIVIOR PLC - INDIVIOR MAKES STATEMENT ON COURT DECISION.INDIVIOR PLC - DISAPPOINTED THAT U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT HAS VACATED PRELIMINARY INJUNCTION AGAINST DR. REDDY'S LABORATORIES.INDIVIOR PLC - IN PROCESS OF INTERPRETING RULING IN ITS ENTIRETY AND WILL ISSUE A STATEMENT ON ITS IMPLICATIONS ONCE THIS REVIEW HAS BEEN COMPLETED.INDIVIOR PLC - WILL CONTINUE TO PURSUE ONGOING INFRINGEMENT CASES AGAINST DRL TO PROTECT SUBOXONE SUBLINGUAL FILM PATENT PORTFOLIO.  Full Article

Indivior Cuts FY Sublocade Rev Forecast To $8 Mln - $10 Mln
Wednesday, 26 Sep 2018 

Sept 26 (Reuters) - Indivior PLC ::INDIVIOR PROVIDES BUSINESS UPDATE.REVISED FY 2018 GUIDANCE OF NET REVENUE OF $990-$1,020 MILLION.REVISED FY 2018 NET INCOME IN A RANGE OF $230-$255 MILLION, EXCLUDING EXCEPTIONAL ITEMS AND AT CONSTANT FX..NET REVENUE EXPECTATIONS FOR SUBLOCADE ARE EXPECTED TO BE BETWEEN $8 TO $10 MILLION.SEES PRE-TAX SAVINGS OF $55 MILLION FROM COST ACTIONS GROUP IS TAKING TO STREAMLINE ORGANIZATION.SEES FINANCE EXPENSE BENEFITS FROM PREPAYMENT OF $150M OF TERM LOAN FACILITIES FOR 2018.WILL INCUR EXCEPTIONAL COSTS OF APPROXIMATELY $13 MILLION PRE-TAX IN FY 2018 TO ACHIEVE COST SAVINGS.SUBLOCADE NET REVENUE DEVELOPMENT CONTINUES TO BE IMPACTED BY INEFFICIENCIES ASSOCIATED WITH PRIOR AUTHORIZATION PROCESS ACROSS PAYORS.SUBLOCADE NET REVENUE FOR Q3 IS LIKELY TO BE IN RANGE OF $3 TO $4 MILLION.WITH SUBLOCADE, HAVE SUBSTANTIALLY UNDERESTIMATED LAG TIME ASSOCIATED WITH APPROVAL OF MEDICAL BENEFIT COVERAGE OF INDIVIDUAL PATIENTS.REMAIN CONFIDENT IN ACHIEVING PEAK SUBLOCADE™ NET REVENUE OF $1 BILLION-PLUS.LONG-TERM FUNDAMENTAL DRIVERS OF SUBLOCADE REMAIN POSITIVE.COST SAVINGS INITIATIVES EXPECTED TO GENERATE ANNUAL PRE-TAX SAVINGS RANGING FROM $80 TO $100 MILLION IN FY 2019.COST ACTIONS INCLUDE ELIMINATING TARGETED SG&A COSTS AND EXTERNAL CONSULTING SERVICES, RESIZING GLOBAL SUPPORT FUNCTIONS.COST ACTIONS INCLUDE REPRIORITIZING RESEARCH AND DEVELOPMENT ACTIVITIES.  Full Article

DURECT Announces Receipt Of $5 Mln Milestone Payment From Indivior
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - DURECT Corp ::DURECT ANNOUNCES RECEIPT OF $5 MILLION MILESTONE PAYMENT FROM INDIVIOR.DURECT - PAYMENT TRIGGERED BY INDIVIOR'S APPROVAL OF NEW DRUG APPLICATION FOR PERSERIS (RISPERIDONE) IN JULY 2018.  Full Article

Indivior says US court expedites Dr Reddy Laboratories' appeal
Monday, 30 Jul 2018 

July 30 (Reuters) - Indivior PLC ::U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT HAS GRANTED-IN-PART A MOTION TO EXPEDITE DR. REDDY LABORATORIES' APPEAL OF JULY 13, 2018 PRELIMINARY INJUNCTION (PI).PI, GRANTED BY DISTRICT OF NEW JERSEY, PROHIBITS DRL FROM USING, IMPORTING, SELLING, OR OFFERING TO SELL ITS GENERIC BUPRENORPHINE/NALOXONE SUBLINGUAL FILM PRODUCT.IN LIGHT OF CAFC'S DECISION TO GRANT DRL AN EXPEDITED APPEAL, INDIVIOR, AS INDICATED IN ITS H1 2018 RESULTS ANNOUNCEMENT, WILL NOW REVIEW APPROPRIATE LAUNCH TIMING FOR PERSERIS™ (RISPERIDONE) EXTENDED-RELEASE INJECTION.  Full Article

UK Stocks-Factors to watch on Dec 19

Dec 19 - Britain's FTSE 100 index is seen 11 points lower at 6,691 on Wednesday, according to financial bookmakers. * RBS: Royal Bank of Scotland has appointed Katie Murray as chief financial officer, the bank said on Tuesday, making permanent a role she has held on an interim basis since August. * INDIVIOR: Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug. * GLE